Patients help Clinuvel win CHMP recommendation for orphan Scenesse
This article was originally published in Scrip
Executive Summary
Australia's Clinuvel has won its first approval recommendation worldwide for its orphan drug Scenesse (afamelanotide), which is used to treat a rare light intolerance condition. Europe's CHMP recommended the drug under exceptional circumstances, after hearing from patients living with the condition.